C4 Therapeutics has dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, an oral IKZF1/3 degrader, combined with dexamethasone for patients with RRMM.
Patients with HIV showed lower cases of steatotic liver disease when switched to ViiV Healthcare’s Dovato compared to ...
The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway” ...
In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema ...
Compass will now seek approval for COMP360 in TRD, which could become the first classic psychedelic to gain the FDA’s ...
Senti Biosciences has completed enrolment of patients in its Phase I clinical trial assessing SENTI-202 in adults with ...
Teva Pharmaceuticals and Sanofi’s monoclonal antibody (mAb) has shown durable clinical and endoscopic efficacy in a Phase IIb ...
The North Midlands CRDC has recruited its first patient, representing the UK’s initial participation in a clinical trial of ...
Prasad and Makary disagree that some may believe this move to just one pivotal trial shows the FDA relaxing its standards.
Roche's Gazyva could become the first drug to gain approval in membranous nephropathy, pending regulatory decisions from the ...
Another of Pfizer’s Braftovi regimens has shown benefit in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation.
CStone Pharmaceuticals' IND application has received FDA clearance, enabling the company to initiate a Phase II trial of its trispecific antibody CS2009.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results